---
document_datetime: 2025-12-02 06:43:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/iqirvo.html
document_name: iqirvo.html
version: success
processing_time: 0.1104685
conversion_datetime: 2025-12-25 09:45:33.061162
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Iqirvo

[RSS](/en/individual-human-medicine.xml/246161)

##### Authorised

This medicine is authorised for use in the European Union

elafibranor Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Iqirvo](#news-on)
- [More information on Iqirvo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Iqirvo is used to treat adults with a liver disease known as primary biliary cholangitis.

Primary biliary cholangitis is an autoimmune condition in which there is gradual destruction of the bile ducts in the liver. These ducts transport fluid called bile from the liver to the intestines, where it is used to help digest fats. As a result of the damage to the ducts, bile builds up in the liver causing damage to liver tissue. This may lead to scarring and liver failure and may increase the risk of liver cancer.

Iqirvo is used together with another medicine, ursodeoxycholic acid (UDCA), in patients for whom UDCA alone does not work well enough, and on its own in patients who cannot take UDCA.

Primary biliary cholangitis is rare, and Iqirvo was designated an 'orphan medicine' (a medicine used in rare diseases) on 25 July 2019. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2182) .

Iqirvo contains the active substance elafibranor.

Expand section

Collapse section

## How is Iqirvo used?

Iqirvo is available as tablets to be taken by mouth once a day. The medicine can only be obtained with a prescription.

For more information about using Iqirvo, see the package leaflet or contact your doctor or pharmacist.

## How does Iqirvo work?

The active substance in Iqirvo, elafibranor, works by attaching to and activating cell receptors (targets) called 'PPAR receptors', which are thought to be involved in controlling the levels of bile acid and in the process of liver inflammation and scarring. By activating PPARs, Iqirvo regulates the levels of bile acid. The medicine also has an anti-inflammatory effect on the liver.

## What benefits of Iqirvo have been shown in studies?

Iqirvo was compared with placebo (a dummy treatment) in a main study involving 161 adults with primary biliary cholangitis. The majority of patients had been taking UDCA for at least 1 year and continued taking it during the study but some patients had stopped taking UDCA due to side effects. The measure of effectiveness was based on the number of patients whose blood levels of the substances ALP and bilirubin (markers of liver damage) decreased to a level considered normal (for both ALP and bilirubin) and by at least 15% (for ALP) after 1 year of treatment.

The study showed that Iqirvo was more effective than placebo at reducing the blood levels of ALP and bilirubin. Overall, levels decreased by the required amount in around 51% (55 out of 108) of patients treated with Iqirvo, compared with around 4% (2 out of 53) of patients on placebo.

## What are the risks associated with Iqirvo?

For the full list of side effects and restrictions with Iqirvo, see the package leaflet.

The most common side effects with Iqirvo (which may affect more than 1 in 10 people) include abdominal (belly) pain, diarrhoea, nausea (feeling sick) and vomiting. In the clinical study, these side effects were mostly mild to moderate in severity, occurred early during treatment and tended to resolve within days to a few weeks.

Iqirvo must not be used in women who are pregnant, could be pregnant or in women who are able to have children when they do not use contraception.

## Why is Iqirvo authorised in the EU?

Patients with primary biliary cholangitis have limited treatment options. Iqirvo has been shown to reduce the blood levels of ALP and bilirubin in patients with primary biliary cholangitis. The extent of the reductions in ALP and bilirubin is considered indicative of an improvement in the condition of the liver. However, as primary biliary cholangitis progresses very slowly, it needs to be confirmed in a further study if these findings translate into long-term clinical benefits. The safety profile of the medicine was considered to be favourable, with side effects that were tolerable and usually resolved in a short time.

The European Medicines Agency therefore decided that Iqirvo's benefits are greater than its risks and it can be authorised for use in the EU.

Iqirvo has been given conditional authorisation. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while awaiting further evidence.

The company must provide further data on Iqirvo. To confirm the safety and effectiveness of Iqirvo in adults with primary biliary cholangitis, the company must conduct a study to investigate the long-term clinical benefits in patients with primary biliary cholangitis treated with Iqirvo. Every year, the Agency will review any new information that becomes available.

## What measures are being taken to ensure the safe and effective use of Iqirvo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Iqirvo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Iqirvo are continuously monitored. Suspected side effects reported with Iqirvo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Iqirvo

Iqirvo received a conditional marketing authorisation valid throughout the EU on 19 September 2024.

Iqirvo : EPAR - Medicine overview

Reference Number: EMA/417400/2024

English (EN) (122.35 KB - PDF)

**First published:** 20/09/2024

[View](/en/documents/overview/iqirvo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-631)

български (BG) (147.99 KB - PDF)

**First published:**

20/09/2024

[View](/bg/documents/overview/iqirvo-epar-medicine-overview_bg.pdf)

español (ES) (121.65 KB - PDF)

**First published:**

20/09/2024

[View](/es/documents/overview/iqirvo-epar-medicine-overview_es.pdf)

čeština (CS) (145.42 KB - PDF)

**First published:**

20/09/2024

[View](/cs/documents/overview/iqirvo-epar-medicine-overview_cs.pdf)

dansk (DA) (121.46 KB - PDF)

**First published:**

20/09/2024

[View](/da/documents/overview/iqirvo-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.83 KB - PDF)

**First published:**

20/09/2024

[View](/de/documents/overview/iqirvo-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.45 KB - PDF)

**First published:**

20/09/2024

[View](/et/documents/overview/iqirvo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (146.67 KB - PDF)

**First published:**

20/09/2024

[View](/el/documents/overview/iqirvo-epar-medicine-overview_el.pdf)

français (FR) (122.9 KB - PDF)

**First published:**

20/09/2024

[View](/fr/documents/overview/iqirvo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (144.49 KB - PDF)

**First published:**

20/09/2024

[View](/hr/documents/overview/iqirvo-epar-medicine-overview_hr.pdf)

italiano (IT) (120.36 KB - PDF)

**First published:**

20/09/2024

[View](/it/documents/overview/iqirvo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.72 KB - PDF)

**First published:**

20/09/2024

[View](/lv/documents/overview/iqirvo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (144.82 KB - PDF)

**First published:**

20/09/2024

[View](/lt/documents/overview/iqirvo-epar-medicine-overview_lt.pdf)

magyar (HU) (143.44 KB - PDF)

**First published:**

20/09/2024

[View](/hu/documents/overview/iqirvo-epar-medicine-overview_hu.pdf)

Malti (MT) (146.15 KB - PDF)

**First published:**

20/09/2024

[View](/mt/documents/overview/iqirvo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.57 KB - PDF)

**First published:**

20/09/2024

[View](/nl/documents/overview/iqirvo-epar-medicine-overview_nl.pdf)

polski (PL) (147.42 KB - PDF)

**First published:**

20/09/2024

[View](/pl/documents/overview/iqirvo-epar-medicine-overview_pl.pdf)

português (PT) (123.07 KB - PDF)

**First published:**

20/09/2024

[View](/pt/documents/overview/iqirvo-epar-medicine-overview_pt.pdf)

română (RO) (141.34 KB - PDF)

**First published:**

20/09/2024

[View](/ro/documents/overview/iqirvo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (144.8 KB - PDF)

**First published:**

20/09/2024

[View](/sk/documents/overview/iqirvo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.65 KB - PDF)

**First published:**

20/09/2024

[View](/sl/documents/overview/iqirvo-epar-medicine-overview_sl.pdf)

Suomi (FI) (119.48 KB - PDF)

**First published:**

20/09/2024

[View](/fi/documents/overview/iqirvo-epar-medicine-overview_fi.pdf)

svenska (SV) (120.02 KB - PDF)

**First published:**

20/09/2024

[View](/sv/documents/overview/iqirvo-epar-medicine-overview_sv.pdf)

Iqirvo : EPAR - Risk management plan

English (EN) (6.45 MB - PDF)

**First published:** 20/09/2024

[View](/en/documents/rmp/iqirvo-epar-risk-management-plan_en.pdf)

## Product information

Iqirvo : EPAR - Product information

English (EN) (365.92 KB - PDF)

**First published:** 20/09/2024

**Last updated:** 28/07/2025

[View](/en/documents/product-information/iqirvo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-934)

български (BG) (397.72 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/bg/documents/product-information/iqirvo-epar-product-information_bg.pdf)

español (ES) (333.92 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/es/documents/product-information/iqirvo-epar-product-information_es.pdf)

čeština (CS) (368.85 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/cs/documents/product-information/iqirvo-epar-product-information_cs.pdf)

dansk (DA) (7.75 MB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/da/documents/product-information/iqirvo-epar-product-information_da.pdf)

Deutsch (DE) (419.71 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/de/documents/product-information/iqirvo-epar-product-information_de.pdf)

eesti keel (ET) (335.82 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/et/documents/product-information/iqirvo-epar-product-information_et.pdf)

ελληνικά (EL) (459.73 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/el/documents/product-information/iqirvo-epar-product-information_el.pdf)

français (FR) (411.41 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/fr/documents/product-information/iqirvo-epar-product-information_fr.pdf)

hrvatski (HR) (363.01 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/hr/documents/product-information/iqirvo-epar-product-information_hr.pdf)

íslenska (IS) (349.82 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/is/documents/product-information/iqirvo-epar-product-information_is.pdf)

italiano (IT) (383.41 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/it/documents/product-information/iqirvo-epar-product-information_it.pdf)

latviešu valoda (LV) (368.13 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/lv/documents/product-information/iqirvo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (381.31 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/lt/documents/product-information/iqirvo-epar-product-information_lt.pdf)

magyar (HU) (414.69 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/hu/documents/product-information/iqirvo-epar-product-information_hu.pdf)

Malti (MT) (423.24 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/mt/documents/product-information/iqirvo-epar-product-information_mt.pdf)

Nederlands (NL) (400.13 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/nl/documents/product-information/iqirvo-epar-product-information_nl.pdf)

norsk (NO) (420.72 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/no/documents/product-information/iqirvo-epar-product-information_no.pdf)

polski (PL) (373.55 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/pl/documents/product-information/iqirvo-epar-product-information_pl.pdf)

português (PT) (319.54 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/pt/documents/product-information/iqirvo-epar-product-information_pt.pdf)

română (RO) (381.37 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/ro/documents/product-information/iqirvo-epar-product-information_ro.pdf)

slovenčina (SK) (371.49 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/sk/documents/product-information/iqirvo-epar-product-information_sk.pdf)

slovenščina (SL) (361.71 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/sl/documents/product-information/iqirvo-epar-product-information_sl.pdf)

Suomi (FI) (367.71 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/fi/documents/product-information/iqirvo-epar-product-information_fi.pdf)

svenska (SV) (408.47 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/sv/documents/product-information/iqirvo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000285287 28/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Iqirvo : EPAR - All authorised presentations

English (EN) (59.21 KB - PDF)

**First published:** 20/09/2024

**Last updated:** 28/07/2025

[View](/en/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-629)

български (BG) (67.86 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/bg/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_bg.pdf)

español (ES) (59.47 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/es/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.36 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/cs/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (59.69 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/da/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.33 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/de/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (59.57 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/et/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (74.15 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/el/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_el.pdf)

français (FR) (59.04 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/fr/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (76.89 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/hr/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (58.88 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/is/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (59.62 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/it/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.61 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/lv/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (76.26 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/lt/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (75.13 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/hu/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (77.71 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/mt/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.49 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/nl/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.06 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/no/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_no.pdf)

polski (PL) (69.14 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/pl/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.66 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/pt/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.48 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/ro/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.06 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/sk/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (76.03 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/sl/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.65 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/fi/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.15 KB - PDF)

**First published:**

20/09/2024

**Last updated:**

28/07/2025

[View](/sv/documents/all-authorised-presentations/iqirvo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Iqirvo Active substance Elafibranor International non-proprietary name (INN) or common name elafibranor Therapeutic area (MeSH) Liver Cirrhosis, Biliary Anatomical therapeutic chemical (ATC) code A05AX06

### Pharmacotherapeutic group

Bile and liver therapy

### Therapeutic indication

Iqirvo is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

## Authorisation details

EMA product number EMEA/H/C/006231

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Ipsen Pharma

70 rue Balard 75015 Paris France

Opinion adopted 25/07/2024 Marketing authorisation issued 19/09/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Iqirvo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.1 KB - PDF)

**First published:** 06/05/2025

**Last updated:** 13/08/2025

[View](/en/documents/procedural-steps-after/iqirvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Iqirvo : Orphan Maintenance Assessment Report - initial authorisation

Adopted

Reference Number: EMA/OD/0000173044

English (EN) (566.44 KB - PDF)

**First published:** 20/09/2024

[View](/en/documents/orphan-maintenance-report/iqirvo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Iqirvo : EPAR - Public assessment report

Reference Number: EMA/372188/2024

English (EN) (2.51 MB - PDF)

**First published:** 20/09/2024

[View](/en/documents/assessment-report/iqirvo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Iqirvo

Reference Number: EMA/CHMP/327112/2024

English (EN) (161.65 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-iqirvo_en.pdf)

#### News on Iqirvo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

#### More information on Iqirvo

- [EU/3/19/2182 - orphan designation for treatment of primary biliary cholangitis](/en/medicines/human/orphan-designations/eu-3-19-2182)

**This page was last updated on** 28/07/2025

## Share this page

[Back to top](#main-content)